Oculis to Present Privosegtor and PIONEER Program at APOIS Congress and CNS Summit
Valid market news retained in the public archive without immediate LiveCast distribution.
Story updates
09:43:40 AM UTC
SquawkNews
Positive Phase 2 ACUITY trial findings support Privosegtor’s potential to deliver a first-in-class neuroprotective treatment for patients with optic neuritis and beyondZUG, Switzerland, October 29th, 2026 -- Oculis Holding AG (Nasdaq: OCS; XICE: OCS) (“Oculis”), a global biopharmaceutical company f…